CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for anyone looking at the stock today. Is the current share price meaningfully supported by what sits on its balance sheet in terms of book value, or is the market asking you to pay well above the company's accounting foundation?
-
Over the past 5 years, the share price has fallen 46.9%, which puts the focus squarely on whether the current valuation can still be anchored to book value rather than past optimism.
-
The recent appointment of Sivakesava Sakhamuri as Chief Technical Officer may support expectations that CRISPR Therapeutics can scale manufacturing and technical operations, which could influence how investors think about future capital needs and the strength of its asset base.
-
Your read on CRISPR Therapeutics is one view; the desks covering it have another. See what analysts think CRISPR Therapeutics's shares could be worth .
The issue now is whether the stock price around US$49.99 is reasonably aligned with CRISPR Therapeutics' book value when set against the industry average.
If you are weighing whether CRISPR Therapeutics' US$49.99 share price lines up with its book value, it can help to compare that question across 34 high quality undervalued stocks
Has CRISPR Therapeutics Run Too Far on Book Value?
P/B tends to fit CRISPR Therapeutics because investors are often weighing cash, investments and other tangible resources against an early stage biotech pipeline. On this measure, the stock trades on a P/B of about 2.8x compared with an industry average of roughly 1.8x for biotechs. That gap means the market is asking you to pay a higher price for each dollar of CRISPR Therapeutics' net assets than is typical across the sector.
Because the new Chief Technical Officer appointment points to heavier focus on scaling manufacturing, the current 2.8x multiple also reflects expectations that the existing asset base can support that build out despite higher capital needs. Set against peers that on average trade closer to 10.5x book, the shares may appear cheaper than some direct comparators yet still expensive relative to the broader biotech industry yardstick. Explore the numbers behind CRISPR Therapeutics's P/B valuation .
The CRISPR Therapeutics Narrative: What Would Justify Today's Price?
Simply Wall St Narratives for CRISPR Therapeutics pick up from this valuation puzzle and outline which potential paths for growth, profitability, and earnings would need to occur for the stock to be worth markedly more or meaningfully less than it is today. All of this is hosted on the firm's Community page. Each viewpoint is built as a thesis that can be tracked over time, allowing you to see how its idea of fair value holds up as the business develops.
CRISPR Therapeutics splits opinion in the community, with some holders leaning into the late stage pipeline and others focused on execution risk and dilution.
Bull case: 43% undervalued
"Progression of CTX310 into later stage development following Phase 1a data that showed up to 80% ANGPTL3 reduction in the liver and around 50% LDL and triglyceride reductions for at least a year positions CRISPR Therapeutics to enter large cardiometabolic markets..."
Discover why this Narrative puts CRISPR Therapeutics at 43% undervalued .
Bear case: 14% overvalued
"The current valuation, with a market value of roughly US$3.5b compared with about US$2.4b of cash and a Neutral rating from UBS, implies limited upside for the CRISPR Therapeutics share price unless the pipeline delivers clear, near-term proof of value..."
Explore why this Narrative puts CRISPR Therapeutics at 14% overvalued .
Before acting on CRISPR Therapeutics' valuation, there is one more angle to check
The figures only tell part of the story, because the people setting priorities and their pay structures can tilt risk and reward in very different directions. See who runs CRISPR Therapeutics and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CRSP .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
